Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Guanine | 82 | 2011 | 208 | 8.190 |
Why?
|
Antineoplastic Agents | 67 | 2023 | 2358 | 6.700 |
Why?
|
Cisplatin | 37 | 2023 | 612 | 6.590 |
Why?
|
Pharmacogenetics | 40 | 2022 | 434 | 6.310 |
Why?
|
Polymorphism, Single Nucleotide | 68 | 2020 | 2357 | 5.860 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 80 | 2011 | 118 | 4.370 |
Why?
|
Genome-Wide Association Study | 48 | 2022 | 1621 | 4.150 |
Why?
|
Peripheral Nervous System Diseases | 10 | 2022 | 85 | 4.070 |
Why?
|
Drug Resistance, Neoplasm | 30 | 2021 | 592 | 3.200 |
Why?
|
Genetic Variation | 27 | 2019 | 1351 | 2.780 |
Why?
|
Genome, Human | 25 | 2018 | 756 | 2.740 |
Why?
|
Neoplasms | 26 | 2022 | 2898 | 2.660 |
Why?
|
Tinnitus | 5 | 2023 | 21 | 2.650 |
Why?
|
Testicular Neoplasms | 7 | 2023 | 105 | 2.560 |
Why?
|
Methyltransferases | 50 | 2008 | 182 | 2.480 |
Why?
|
Antineoplastic Agents, Alkylating | 24 | 2015 | 138 | 2.450 |
Why?
|
Quantitative Trait Loci | 22 | 2017 | 576 | 2.360 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 8 | 2020 | 199 | 2.300 |
Why?
|
Hearing Loss | 6 | 2023 | 56 | 2.300 |
Why?
|
Cancer Survivors | 6 | 2023 | 85 | 2.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 12 | 2015 | 276 | 2.020 |
Why?
|
Cell Line, Tumor | 36 | 2019 | 2426 | 2.010 |
Why?
|
Cell Line | 40 | 2018 | 2468 | 1.840 |
Why?
|
Carboplatin | 13 | 2018 | 286 | 1.810 |
Why?
|
Paclitaxel | 10 | 2018 | 460 | 1.810 |
Why?
|
Gene Expression | 16 | 2014 | 1284 | 1.760 |
Why?
|
Carmustine | 34 | 2007 | 70 | 1.730 |
Why?
|
Neurotoxicity Syndromes | 3 | 2022 | 28 | 1.720 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 27 | 2021 | 2436 | 1.710 |
Why?
|
Humans | 232 | 2023 | 86617 | 1.680 |
Why?
|
Cyclophosphamide | 12 | 2014 | 299 | 1.660 |
Why?
|
Gene Expression Regulation | 12 | 2021 | 1920 | 1.650 |
Why?
|
Lymphocytes | 9 | 2018 | 464 | 1.620 |
Why?
|
Apoptosis | 13 | 2014 | 1683 | 1.550 |
Why?
|
Dacarbazine | 18 | 2014 | 102 | 1.540 |
Why?
|
Antimetabolites, Antineoplastic | 9 | 2020 | 236 | 1.520 |
Why?
|
Induced Pluripotent Stem Cells | 5 | 2021 | 104 | 1.430 |
Why?
|
MicroRNAs | 7 | 2018 | 534 | 1.410 |
Why?
|
Cell Proliferation | 9 | 2012 | 1578 | 1.330 |
Why?
|
Drug Discovery | 4 | 2012 | 103 | 1.210 |
Why?
|
Enzyme Inhibitors | 24 | 2009 | 639 | 1.200 |
Why?
|
Etoposide | 8 | 2021 | 196 | 1.190 |
Why?
|
Polymorphism, Genetic | 15 | 2015 | 819 | 1.160 |
Why?
|
DNA Repair | 28 | 2007 | 356 | 1.140 |
Why?
|
Precision Medicine | 5 | 2017 | 395 | 1.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 13 | 2020 | 1197 | 1.130 |
Why?
|
Neurons | 6 | 2021 | 1546 | 1.100 |
Why?
|
Cytarabine | 7 | 2020 | 218 | 1.100 |
Why?
|
Cell Survival | 21 | 2019 | 969 | 1.090 |
Why?
|
Alkylating Agents | 7 | 2008 | 32 | 1.070 |
Why?
|
Vincristine | 3 | 2021 | 111 | 1.060 |
Why?
|
Genotype | 22 | 2020 | 1851 | 1.050 |
Why?
|
Gene Expression Profiling | 13 | 2021 | 1384 | 0.980 |
Why?
|
Disease Susceptibility | 2 | 2019 | 193 | 0.970 |
Why?
|
Camptothecin | 7 | 2009 | 189 | 0.970 |
Why?
|
Glutathione Transferase | 5 | 2009 | 111 | 0.940 |
Why?
|
Tumor Cells, Cultured | 33 | 2005 | 1041 | 0.900 |
Why?
|
Biomarkers, Tumor | 6 | 2020 | 1464 | 0.900 |
Why?
|
Brain Neoplasms | 13 | 2014 | 763 | 0.880 |
Why?
|
Genetic Predisposition to Disease | 15 | 2019 | 2270 | 0.870 |
Why?
|
Speech Perception | 1 | 2022 | 71 | 0.840 |
Why?
|
Cytosine | 6 | 2015 | 127 | 0.840 |
Why?
|
Pemetrexed | 3 | 2018 | 76 | 0.830 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2021 | 375 | 0.830 |
Why?
|
HapMap Project | 9 | 2014 | 47 | 0.820 |
Why?
|
Ribonucleoproteins, Small Nuclear | 1 | 2021 | 20 | 0.810 |
Why?
|
Genes | 2 | 2013 | 305 | 0.810 |
Why?
|
Cytochrome P-450 Enzyme System | 5 | 2015 | 79 | 0.800 |
Why?
|
Daunorubicin | 4 | 2014 | 78 | 0.770 |
Why?
|
Leukemia, Myeloid, Acute | 8 | 2020 | 763 | 0.770 |
Why?
|
Organoplatinum Compounds | 3 | 2011 | 94 | 0.770 |
Why?
|
Phenotype | 16 | 2015 | 2378 | 0.760 |
Why?
|
Cell Cycle Proteins | 3 | 2017 | 388 | 0.750 |
Why?
|
Nuclear Proteins | 5 | 2015 | 696 | 0.730 |
Why?
|
Colistin | 2 | 2017 | 7 | 0.720 |
Why?
|
DNA, Neoplasm | 7 | 2006 | 265 | 0.710 |
Why?
|
Population Groups | 2 | 2010 | 41 | 0.710 |
Why?
|
Biomarkers, Pharmacological | 4 | 2012 | 22 | 0.710 |
Why?
|
Genetic Linkage | 4 | 2008 | 623 | 0.700 |
Why?
|
Transcription Factors | 9 | 2017 | 1565 | 0.680 |
Why?
|
Membrane Proteins | 5 | 2018 | 1196 | 0.680 |
Why?
|
Acid Anhydride Hydrolases | 1 | 2018 | 13 | 0.670 |
Why?
|
Animals | 79 | 2021 | 26582 | 0.670 |
Why?
|
Neoplasm Proteins | 4 | 2017 | 532 | 0.660 |
Why?
|
Proteomics | 2 | 2017 | 212 | 0.650 |
Why?
|
Oligonucleotide Array Sequence Analysis | 8 | 2011 | 689 | 0.650 |
Why?
|
Drug Synergism | 16 | 2017 | 303 | 0.650 |
Why?
|
Male | 69 | 2023 | 40958 | 0.650 |
Why?
|
Adaptor Proteins, Signal Transducing | 4 | 2015 | 302 | 0.650 |
Why?
|
Ifosfamide | 4 | 2020 | 49 | 0.640 |
Why?
|
Liver | 15 | 2005 | 1230 | 0.640 |
Why?
|
Transfection | 14 | 2007 | 896 | 0.620 |
Why?
|
Electroporation | 3 | 2001 | 55 | 0.590 |
Why?
|
CHO Cells | 10 | 2007 | 187 | 0.590 |
Why?
|
Antigens, CD34 | 3 | 2001 | 158 | 0.570 |
Why?
|
Drug Therapy | 4 | 2011 | 70 | 0.570 |
Why?
|
Hematopoietic Stem Cells | 4 | 2006 | 292 | 0.570 |
Why?
|
Carboxylic Ester Hydrolases | 3 | 2002 | 23 | 0.570 |
Why?
|
Fluorouracil | 7 | 2014 | 556 | 0.560 |
Why?
|
Risk Factors | 9 | 2023 | 5417 | 0.560 |
Why?
|
Carboxylesterase | 3 | 2004 | 10 | 0.540 |
Why?
|
Cells, Cultured | 8 | 2021 | 2818 | 0.540 |
Why?
|
Proteins | 5 | 2014 | 777 | 0.540 |
Why?
|
Female | 64 | 2021 | 44509 | 0.530 |
Why?
|
Carrier Proteins | 4 | 2015 | 673 | 0.520 |
Why?
|
Dose-Response Relationship, Drug | 14 | 2018 | 1961 | 0.520 |
Why?
|
Glioma | 6 | 2007 | 285 | 0.510 |
Why?
|
Glutamates | 2 | 2011 | 89 | 0.510 |
Why?
|
Alternative Splicing | 4 | 2012 | 201 | 0.510 |
Why?
|
DNA Damage | 9 | 2011 | 366 | 0.500 |
Why?
|
Mice | 38 | 2021 | 11352 | 0.500 |
Why?
|
Antibiotics, Antineoplastic | 5 | 2014 | 114 | 0.500 |
Why?
|
Gene Dosage | 3 | 2011 | 207 | 0.490 |
Why?
|
Deoxycytidine | 2 | 2014 | 237 | 0.490 |
Why?
|
Breast Neoplasms | 7 | 2020 | 2887 | 0.490 |
Why?
|
Cricetinae | 13 | 2007 | 560 | 0.480 |
Why?
|
Repressor Proteins | 1 | 2017 | 403 | 0.480 |
Why?
|
Haplotypes | 4 | 2014 | 642 | 0.470 |
Why?
|
Glutathione | 4 | 2004 | 104 | 0.470 |
Why?
|
Adenocarcinoma | 2 | 2018 | 1169 | 0.470 |
Why?
|
Adult | 31 | 2022 | 25640 | 0.460 |
Why?
|
RNA-Binding Proteins | 2 | 2012 | 246 | 0.460 |
Why?
|
Adenine Nucleotides | 1 | 2013 | 63 | 0.450 |
Why?
|
Neuroblastoma | 2 | 2014 | 374 | 0.450 |
Why?
|
Arabinonucleosides | 1 | 2013 | 39 | 0.450 |
Why?
|
Homeodomain Proteins | 1 | 2017 | 536 | 0.450 |
Why?
|
DNA Methylation | 7 | 2015 | 628 | 0.450 |
Why?
|
Glioblastoma | 9 | 2014 | 255 | 0.440 |
Why?
|
Universities | 1 | 2013 | 135 | 0.440 |
Why?
|
Child | 14 | 2021 | 6926 | 0.440 |
Why?
|
Colonic Neoplasms | 10 | 1999 | 556 | 0.430 |
Why?
|
Inhibitory Concentration 50 | 6 | 2011 | 64 | 0.430 |
Why?
|
Drug Resistance | 11 | 2018 | 256 | 0.420 |
Why?
|
Cortactin | 1 | 2011 | 11 | 0.420 |
Why?
|
DNA Repair Enzymes | 3 | 2014 | 52 | 0.420 |
Why?
|
Genomics | 5 | 2014 | 720 | 0.410 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 746 | 0.410 |
Why?
|
Genealogy and Heraldry | 1 | 2011 | 13 | 0.410 |
Why?
|
Inactivation, Metabolic | 1 | 2011 | 8 | 0.410 |
Why?
|
Microsomes, Liver | 5 | 2015 | 49 | 0.410 |
Why?
|
Lomustine | 9 | 1992 | 26 | 0.400 |
Why?
|
Aged | 27 | 2020 | 18402 | 0.400 |
Why?
|
Membrane Transport Proteins | 1 | 2012 | 166 | 0.390 |
Why?
|
Gene Frequency | 6 | 2017 | 677 | 0.390 |
Why?
|
Platinum Compounds | 3 | 2010 | 31 | 0.390 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2017 | 1313 | 0.390 |
Why?
|
Follow-Up Studies | 7 | 2020 | 3636 | 0.390 |
Why?
|
Epigenesis, Genetic | 3 | 2013 | 479 | 0.380 |
Why?
|
Chromosome Mapping | 5 | 2014 | 1074 | 0.380 |
Why?
|
Pharmaceutical Preparations | 2 | 2011 | 92 | 0.380 |
Why?
|
Middle Aged | 30 | 2020 | 25017 | 0.380 |
Why?
|
RNA, Messenger | 7 | 2014 | 1981 | 0.380 |
Why?
|
Transcriptome | 5 | 2015 | 580 | 0.380 |
Why?
|
Cell Cycle | 5 | 2004 | 502 | 0.370 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2009 | 14 | 0.370 |
Why?
|
Databases, Genetic | 6 | 2012 | 260 | 0.360 |
Why?
|
Linkage Disequilibrium | 6 | 2013 | 473 | 0.360 |
Why?
|
Central Nervous System Neoplasms | 5 | 2003 | 81 | 0.360 |
Why?
|
Genes, Regulator | 1 | 2009 | 65 | 0.350 |
Why?
|
Promoter Regions, Genetic | 7 | 2014 | 937 | 0.350 |
Why?
|
Capecitabine | 4 | 2020 | 96 | 0.350 |
Why?
|
Mice, Nude | 18 | 2005 | 790 | 0.350 |
Why?
|
Biomedical Research | 1 | 2013 | 375 | 0.340 |
Why?
|
Hyaluronan Receptors | 1 | 2009 | 36 | 0.340 |
Why?
|
Folic Acid | 1 | 2009 | 60 | 0.340 |
Why?
|
Lymphocyte Activation | 1 | 2012 | 728 | 0.340 |
Why?
|
Inheritance Patterns | 1 | 2008 | 48 | 0.330 |
Why?
|
DNA | 14 | 2011 | 1294 | 0.330 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2008 | 427 | 0.330 |
Why?
|
DNA Copy Number Variations | 1 | 2009 | 171 | 0.330 |
Why?
|
Young Adult | 9 | 2021 | 5974 | 0.320 |
Why?
|
Cation Transport Proteins | 1 | 2008 | 64 | 0.320 |
Why?
|
B-Lymphocytes | 1 | 2013 | 724 | 0.320 |
Why?
|
Gene Silencing | 2 | 2015 | 172 | 0.320 |
Why?
|
Sex Characteristics | 2 | 2009 | 319 | 0.320 |
Why?
|
Population | 1 | 2008 | 35 | 0.320 |
Why?
|
Phosphoramide Mustards | 3 | 2004 | 4 | 0.320 |
Why?
|
RNA, Small Interfering | 4 | 2015 | 547 | 0.320 |
Why?
|
Chromosomes, Human | 1 | 2008 | 66 | 0.320 |
Why?
|
Anticarcinogenic Agents | 2 | 2000 | 70 | 0.310 |
Why?
|
Pyrazines | 2 | 2000 | 92 | 0.310 |
Why?
|
Antigens, Differentiation | 2 | 2005 | 141 | 0.310 |
Why?
|
Comprehension | 1 | 2008 | 79 | 0.310 |
Why?
|
Prognosis | 9 | 2020 | 3675 | 0.310 |
Why?
|
Survivors | 3 | 2022 | 226 | 0.310 |
Why?
|
Exons | 5 | 2012 | 450 | 0.300 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2021 | 90 | 0.300 |
Why?
|
Signal Transduction | 5 | 2014 | 3241 | 0.300 |
Why?
|
Cell Division | 11 | 2003 | 696 | 0.300 |
Why?
|
Lung Neoplasms | 4 | 2021 | 2262 | 0.300 |
Why?
|
Tumor Suppressor Proteins | 4 | 2014 | 279 | 0.300 |
Why?
|
Geographic Information Systems | 1 | 2006 | 20 | 0.290 |
Why?
|
Endoplasmic Reticulum | 1 | 2008 | 250 | 0.290 |
Why?
|
Methylnitronitrosoguanidine | 7 | 1991 | 16 | 0.290 |
Why?
|
Alkyl and Aryl Transferases | 4 | 1999 | 15 | 0.290 |
Why?
|
Spermine | 2 | 1998 | 18 | 0.290 |
Why?
|
Transplantation, Heterologous | 16 | 2007 | 363 | 0.280 |
Why?
|
Colorectal Neoplasms | 4 | 2014 | 938 | 0.280 |
Why?
|
Mutation | 9 | 2008 | 3967 | 0.280 |
Why?
|
Biomarkers | 3 | 2021 | 1718 | 0.280 |
Why?
|
Genome | 2 | 2006 | 372 | 0.280 |
Why?
|
Mycosis Fungoides | 2 | 2011 | 23 | 0.280 |
Why?
|
Computational Biology | 7 | 2014 | 528 | 0.280 |
Why?
|
Neoplasm Transplantation | 14 | 2002 | 391 | 0.270 |
Why?
|
Health Status | 1 | 2008 | 360 | 0.270 |
Why?
|
Adolescent | 8 | 2021 | 8979 | 0.270 |
Why?
|
Rats | 21 | 2015 | 3990 | 0.270 |
Why?
|
Mitomycin | 1 | 2005 | 29 | 0.260 |
Why?
|
Kinetics | 13 | 2003 | 1513 | 0.260 |
Why?
|
Models, Biological | 5 | 2018 | 1749 | 0.260 |
Why?
|
Head and Neck Neoplasms | 8 | 2011 | 1052 | 0.260 |
Why?
|
CDC2-CDC28 Kinases | 1 | 2004 | 7 | 0.250 |
Why?
|
Ovarian Neoplasms | 1 | 2011 | 744 | 0.250 |
Why?
|
Cytochrome P-450 CYP1A2 | 2 | 2001 | 4 | 0.250 |
Why?
|
Cell Death | 4 | 2011 | 256 | 0.250 |
Why?
|
Platinum | 3 | 2011 | 63 | 0.240 |
Why?
|
Chromatography, High Pressure Liquid | 6 | 1999 | 315 | 0.240 |
Why?
|
Tubulin | 2 | 2015 | 58 | 0.240 |
Why?
|
RNA Interference | 3 | 2014 | 369 | 0.230 |
Why?
|
Case-Control Studies | 6 | 2020 | 1804 | 0.230 |
Why?
|
Tissue Distribution | 6 | 2004 | 290 | 0.230 |
Why?
|
Biotransformation | 6 | 2009 | 50 | 0.230 |
Why?
|
Mesylates | 5 | 1991 | 15 | 0.230 |
Why?
|
Survival Analysis | 3 | 2006 | 1538 | 0.230 |
Why?
|
Proteome | 2 | 2014 | 124 | 0.230 |
Why?
|
Chromosomes, Human, X | 2 | 2015 | 55 | 0.230 |
Why?
|
Base Sequence | 10 | 2014 | 2330 | 0.230 |
Why?
|
Treatment Outcome | 11 | 2013 | 7990 | 0.220 |
Why?
|
Prodrugs | 2 | 2004 | 46 | 0.220 |
Why?
|
Microtubule-Associated Proteins | 2 | 2015 | 176 | 0.220 |
Why?
|
Leukemia | 4 | 2009 | 320 | 0.220 |
Why?
|
Cytosol | 4 | 2011 | 189 | 0.220 |
Why?
|
Astrocytoma | 2 | 2000 | 82 | 0.210 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2021 | 458 | 0.210 |
Why?
|
Sensation Disorders | 1 | 2022 | 23 | 0.210 |
Why?
|
Cohort Studies | 3 | 2021 | 2767 | 0.210 |
Why?
|
Quantitative Trait, Heritable | 2 | 2013 | 124 | 0.210 |
Why?
|
Speech | 1 | 2022 | 84 | 0.210 |
Why?
|
Blotting, Western | 6 | 2011 | 782 | 0.210 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2013 | 199 | 0.210 |
Why?
|
Hypercholesterolemia | 1 | 2023 | 161 | 0.200 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 879 | 0.200 |
Why?
|
Methylnitrosourea | 4 | 1989 | 7 | 0.200 |
Why?
|
Survival Rate | 4 | 2020 | 1860 | 0.200 |
Why?
|
Antibodies | 3 | 2014 | 350 | 0.200 |
Why?
|
Hydrolysis | 4 | 2004 | 141 | 0.200 |
Why?
|
CpG Islands | 4 | 2015 | 151 | 0.200 |
Why?
|
Primary Cell Culture | 1 | 2021 | 72 | 0.200 |
Why?
|
Drug Interactions | 5 | 2005 | 248 | 0.200 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2021 | 49 | 0.200 |
Why?
|
Oligodeoxyribonucleotides | 4 | 1988 | 126 | 0.200 |
Why?
|
Drug Administration Schedule | 7 | 2009 | 916 | 0.200 |
Why?
|
Codon | 2 | 1999 | 124 | 0.190 |
Why?
|
Kidney | 6 | 2013 | 1241 | 0.190 |
Why?
|
Vinblastine | 1 | 2020 | 108 | 0.190 |
Why?
|
Fetal Blood | 1 | 2001 | 90 | 0.190 |
Why?
|
Gene Knockdown Techniques | 1 | 2021 | 236 | 0.190 |
Why?
|
Gene Transfer Techniques | 1 | 2001 | 152 | 0.190 |
Why?
|
Bleomycin | 1 | 2020 | 98 | 0.190 |
Why?
|
Deoxycytidine Kinase | 2 | 2011 | 4 | 0.190 |
Why?
|
Oxidoreductases | 3 | 1999 | 112 | 0.180 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2002 | 151 | 0.180 |
Why?
|
Cell Differentiation | 2 | 2017 | 1458 | 0.180 |
Why?
|
Ketoconazole | 1 | 2000 | 25 | 0.180 |
Why?
|
Mice, Inbred BALB C | 11 | 2005 | 1047 | 0.180 |
Why?
|
Genetic Testing | 2 | 2017 | 535 | 0.180 |
Why?
|
Colonic Polyps | 1 | 2000 | 126 | 0.180 |
Why?
|
Escherichia coli | 7 | 1993 | 597 | 0.170 |
Why?
|
Myosin Heavy Chains | 1 | 2019 | 88 | 0.170 |
Why?
|
Myosin Type II | 1 | 2019 | 50 | 0.170 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2020 | 241 | 0.170 |
Why?
|
Hypogonadism | 1 | 2019 | 37 | 0.170 |
Why?
|
Isoenzymes | 4 | 2001 | 271 | 0.170 |
Why?
|
Antigens, CD | 1 | 2001 | 458 | 0.170 |
Why?
|
Time Factors | 11 | 2014 | 5209 | 0.170 |
Why?
|
Radiotherapy | 2 | 2020 | 328 | 0.170 |
Why?
|
Taxoids | 2 | 2016 | 129 | 0.170 |
Why?
|
Mice, Inbred C57BL | 6 | 2016 | 3092 | 0.170 |
Why?
|
Genital Neoplasms, Female | 1 | 2020 | 107 | 0.170 |
Why?
|
Area Under Curve | 4 | 2008 | 334 | 0.170 |
Why?
|
Vagina | 1 | 2020 | 161 | 0.170 |
Why?
|
Structure-Activity Relationship | 8 | 2001 | 408 | 0.170 |
Why?
|
Naphthoquinones | 1 | 1998 | 5 | 0.170 |
Why?
|
Linear Models | 2 | 2011 | 421 | 0.160 |
Why?
|
Pyrimidines | 3 | 1996 | 370 | 0.160 |
Why?
|
Aged, 80 and over | 10 | 2020 | 6501 | 0.160 |
Why?
|
Molecular Sequence Data | 9 | 2011 | 3030 | 0.160 |
Why?
|
Protein Isoforms | 3 | 2012 | 270 | 0.150 |
Why?
|
Recombinant Proteins | 6 | 2007 | 1014 | 0.150 |
Why?
|
Self Report | 1 | 2019 | 288 | 0.150 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2009 | 72 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 2 | 2 | 2009 | 25 | 0.150 |
Why?
|
Herpesvirus 4, Human | 2 | 2010 | 114 | 0.150 |
Why?
|
Bacteria | 2 | 2020 | 447 | 0.150 |
Why?
|
Drug Screening Assays, Antitumor | 6 | 2014 | 78 | 0.150 |
Why?
|
Medulloblastoma | 5 | 2005 | 36 | 0.150 |
Why?
|
Cell Line, Transformed | 2 | 2008 | 154 | 0.140 |
Why?
|
Age of Onset | 1 | 2017 | 310 | 0.140 |
Why?
|
DNA Modification Methylases | 2 | 2014 | 25 | 0.140 |
Why?
|
Ethylnitrosourea | 2 | 1988 | 30 | 0.140 |
Why?
|
Mutagenicity Tests | 3 | 2006 | 6 | 0.140 |
Why?
|
Quality of Life | 4 | 2020 | 1583 | 0.140 |
Why?
|
Streptozocin | 7 | 1994 | 54 | 0.140 |
Why?
|
Child, Preschool | 6 | 2015 | 3611 | 0.140 |
Why?
|
Polyneuropathies | 1 | 2016 | 27 | 0.140 |
Why?
|
Real-Time Polymerase Chain Reaction | 2 | 2014 | 273 | 0.140 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 47 | 0.140 |
Why?
|
Introns | 3 | 2012 | 289 | 0.140 |
Why?
|
Mice, Knockout | 3 | 2016 | 1924 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-bcr | 1 | 2015 | 7 | 0.130 |
Why?
|
X Chromosome Inactivation | 1 | 2015 | 28 | 0.130 |
Why?
|
Half-Life | 3 | 2003 | 96 | 0.130 |
Why?
|
Epistasis, Genetic | 2 | 2013 | 86 | 0.130 |
Why?
|
Thymine | 4 | 1988 | 17 | 0.130 |
Why?
|
Flow Cytometry | 3 | 2003 | 679 | 0.130 |
Why?
|
Rats, Sprague-Dawley | 6 | 2000 | 1219 | 0.130 |
Why?
|
Acrolein | 2 | 2007 | 4 | 0.130 |
Why?
|
Acetaldehyde | 2 | 2007 | 7 | 0.130 |
Why?
|
Neurites | 1 | 2015 | 35 | 0.130 |
Why?
|
Databases, Nucleic Acid | 1 | 2015 | 41 | 0.130 |
Why?
|
Pedigree | 2 | 2008 | 966 | 0.130 |
Why?
|
Treatment Failure | 2 | 2014 | 285 | 0.130 |
Why?
|
DEAD-box RNA Helicases | 1 | 2015 | 62 | 0.130 |
Why?
|
Oxygenases | 1 | 2014 | 13 | 0.130 |
Why?
|
Glutathione S-Transferase pi | 1 | 2014 | 18 | 0.130 |
Why?
|
Deoxyguanosine | 3 | 2004 | 28 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 3 | 2012 | 860 | 0.130 |
Why?
|
Hand-Foot Syndrome | 1 | 2014 | 1 | 0.130 |
Why?
|
Body Weight | 4 | 2013 | 459 | 0.120 |
Why?
|
Skin Neoplasms | 1 | 1999 | 541 | 0.120 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 111 | 0.120 |
Why?
|
Infusions, Intravenous | 3 | 2007 | 429 | 0.120 |
Why?
|
Cyclohexylamines | 1 | 2014 | 7 | 0.120 |
Why?
|
Cricetulus | 3 | 2007 | 126 | 0.120 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 1994 | 5 | 0.120 |
Why?
|
Sequence Analysis, RNA | 1 | 2015 | 217 | 0.120 |
Why?
|
HEK293 Cells | 2 | 2013 | 615 | 0.120 |
Why?
|
Eye Proteins | 1 | 2015 | 128 | 0.120 |
Why?
|
Plicamycin | 1 | 2013 | 9 | 0.120 |
Why?
|
DNA Mismatch Repair | 2 | 2011 | 52 | 0.120 |
Why?
|
Carcinoma | 2 | 1989 | 436 | 0.120 |
Why?
|
5' Untranslated Regions | 2 | 2004 | 49 | 0.120 |
Why?
|
Prostatic Neoplasms | 2 | 1998 | 1721 | 0.120 |
Why?
|
Ribonucleoside Diphosphate Reductase | 1 | 2013 | 6 | 0.120 |
Why?
|
Glycerol | 1 | 1994 | 32 | 0.120 |
Why?
|
Quality Control | 1 | 2014 | 117 | 0.120 |
Why?
|
Epithelial Cells | 1 | 2018 | 669 | 0.120 |
Why?
|
DNA-Binding Proteins | 4 | 2014 | 1208 | 0.120 |
Why?
|
Amino Acid Sequence | 5 | 2005 | 2062 | 0.120 |
Why?
|
Population Surveillance | 2 | 2012 | 219 | 0.120 |
Why?
|
Cell Cycle Checkpoints | 1 | 2013 | 63 | 0.110 |
Why?
|
Regulatory Factor X Transcription Factors | 1 | 2012 | 11 | 0.110 |
Why?
|
Healthcare Disparities | 1 | 2017 | 370 | 0.110 |
Why?
|
Interleukin-11 | 1 | 2013 | 20 | 0.110 |
Why?
|
Injections, Intravenous | 4 | 2006 | 244 | 0.110 |
Why?
|
Methylation | 6 | 2011 | 251 | 0.110 |
Why?
|
Alleles | 3 | 2005 | 1128 | 0.110 |
Why?
|
3' Untranslated Regions | 2 | 2004 | 92 | 0.110 |
Why?
|
Caspase 1 | 1 | 2012 | 18 | 0.110 |
Why?
|
Salmonella Infections | 1 | 2012 | 18 | 0.110 |
Why?
|
Risk Assessment | 4 | 2014 | 2261 | 0.110 |
Why?
|
Multifactorial Inheritance | 1 | 2014 | 159 | 0.110 |
Why?
|
Salmonella typhimurium | 1 | 2012 | 32 | 0.110 |
Why?
|
Tubulin Modulators | 1 | 2012 | 24 | 0.110 |
Why?
|
Hypoxanthine Phosphoribosyltransferase | 2 | 2008 | 35 | 0.110 |
Why?
|
Age Factors | 1 | 2017 | 1849 | 0.110 |
Why?
|
In Vitro Techniques | 5 | 2015 | 989 | 0.110 |
Why?
|
Methionine | 1 | 2012 | 66 | 0.110 |
Why?
|
Mutagenesis | 2 | 2008 | 199 | 0.110 |
Why?
|
Students | 1 | 2013 | 147 | 0.100 |
Why?
|
Nigeria | 1 | 2012 | 152 | 0.100 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 3 | 2002 | 268 | 0.100 |
Why?
|
Floxuridine | 1 | 2011 | 11 | 0.100 |
Why?
|
Southwestern United States | 1 | 2011 | 8 | 0.100 |
Why?
|
Sezary Syndrome | 1 | 2011 | 8 | 0.100 |
Why?
|
5'-Nucleotidase | 1 | 2011 | 13 | 0.100 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 2 | 2009 | 72 | 0.100 |
Why?
|
Germ Cells | 1 | 2012 | 126 | 0.100 |
Why?
|
DNA Breaks, Double-Stranded | 2 | 2009 | 64 | 0.100 |
Why?
|
Twins, Monozygotic | 1 | 2011 | 57 | 0.100 |
Why?
|
Polyethylene Glycols | 1 | 1994 | 363 | 0.100 |
Why?
|
Interleukin-3 | 2 | 2001 | 36 | 0.100 |
Why?
|
Microfilament Proteins | 1 | 2013 | 208 | 0.100 |
Why?
|
Drug Labeling | 1 | 2011 | 41 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2013 | 302 | 0.100 |
Why?
|
Caspases | 1 | 2011 | 155 | 0.100 |
Why?
|
Disease-Free Survival | 1 | 2014 | 1204 | 0.100 |
Why?
|
DNA, Complementary | 2 | 2002 | 393 | 0.100 |
Why?
|
Maximum Tolerated Dose | 3 | 2008 | 270 | 0.100 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2001 | 112 | 0.100 |
Why?
|
United States Food and Drug Administration | 1 | 2011 | 127 | 0.100 |
Why?
|
HeLa Cells | 3 | 1988 | 498 | 0.100 |
Why?
|
Loss of Heterozygosity | 3 | 2007 | 85 | 0.090 |
Why?
|
Escherichia coli Proteins | 1 | 1991 | 179 | 0.090 |
Why?
|
Cluster Analysis | 4 | 2013 | 369 | 0.090 |
Why?
|
Mutagens | 2 | 2000 | 31 | 0.090 |
Why?
|
Semustine | 1 | 1990 | 2 | 0.090 |
Why?
|
Cell Culture Techniques | 2 | 2001 | 188 | 0.090 |
Why?
|
Rhabdomyosarcoma | 2 | 2003 | 40 | 0.090 |
Why?
|
Vinca Alkaloids | 1 | 2009 | 3 | 0.090 |
Why?
|
Polymerase Chain Reaction | 2 | 2004 | 927 | 0.090 |
Why?
|
Neutropenia | 2 | 2009 | 215 | 0.090 |
Why?
|
Software | 2 | 2014 | 654 | 0.090 |
Why?
|
Topoisomerase II Inhibitors | 3 | 2011 | 27 | 0.090 |
Why?
|
Open Reading Frames | 1 | 2009 | 117 | 0.090 |
Why?
|
Anthracyclines | 1 | 2009 | 37 | 0.090 |
Why?
|
Amino Acid Transport Systems, Basic | 1 | 2008 | 1 | 0.090 |
Why?
|
Recombinant Fusion Proteins | 2 | 2001 | 557 | 0.090 |
Why?
|
Semaphorins | 1 | 2008 | 17 | 0.090 |
Why?
|
Copper-transporting ATPases | 1 | 2008 | 12 | 0.090 |
Why?
|
Protein-Arginine N-Methyltransferases | 1 | 2008 | 12 | 0.090 |
Why?
|
RNA Precursors | 1 | 2009 | 69 | 0.090 |
Why?
|
Genetic Markers | 1 | 2010 | 476 | 0.080 |
Why?
|
Models, Genetic | 3 | 2014 | 926 | 0.080 |
Why?
|
Multidrug Resistance-Associated Proteins | 3 | 2009 | 27 | 0.080 |
Why?
|
Metabolic Networks and Pathways | 1 | 2009 | 79 | 0.080 |
Why?
|
Lod Score | 1 | 2008 | 152 | 0.080 |
Why?
|
Glypicans | 1 | 2008 | 6 | 0.080 |
Why?
|
Caspase 12 | 1 | 2008 | 1 | 0.080 |
Why?
|
Adenosine Triphosphate | 1 | 2010 | 314 | 0.080 |
Why?
|
Chicago | 1 | 2013 | 1379 | 0.080 |
Why?
|
Transcription Factor CHOP | 1 | 2008 | 15 | 0.080 |
Why?
|
Thiones | 2 | 2000 | 10 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 74 | 0.080 |
Why?
|
Cytochrome P-450 CYP1B1 | 1 | 2008 | 9 | 0.080 |
Why?
|
Epoxide Hydrolases | 1 | 2008 | 7 | 0.080 |
Why?
|
Neurofibromin 1 | 1 | 2008 | 8 | 0.080 |
Why?
|
Models, Theoretical | 1 | 2011 | 482 | 0.080 |
Why?
|
Hypertension | 1 | 2017 | 1141 | 0.080 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2009 | 105 | 0.080 |
Why?
|
Melphalan | 2 | 2001 | 97 | 0.080 |
Why?
|
Benzimidazoles | 1 | 2009 | 140 | 0.080 |
Why?
|
Cross-Linking Reagents | 1 | 1988 | 86 | 0.080 |
Why?
|
Thiophenes | 2 | 2000 | 48 | 0.080 |
Why?
|
Caspase 3 | 1 | 2008 | 159 | 0.080 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 44 | 0.080 |
Why?
|
Nucleic Acid Conformation | 1 | 2009 | 332 | 0.080 |
Why?
|
Drug Delivery Systems | 2 | 2007 | 178 | 0.080 |
Why?
|
Peptides | 1 | 1991 | 639 | 0.080 |
Why?
|
Diabetes Mellitus | 1 | 1996 | 806 | 0.080 |
Why?
|
Biological Availability | 2 | 2000 | 92 | 0.080 |
Why?
|
Electronic Health Records | 1 | 2011 | 319 | 0.080 |
Why?
|
Adenosine Triphosphatases | 1 | 2008 | 153 | 0.080 |
Why?
|
Biological Transport | 1 | 2008 | 396 | 0.080 |
Why?
|
Reproducibility of Results | 4 | 2013 | 2705 | 0.080 |
Why?
|
Oxazines | 1 | 2007 | 13 | 0.080 |
Why?
|
Obesity | 1 | 2014 | 963 | 0.080 |
Why?
|
Xanthenes | 1 | 2007 | 23 | 0.080 |
Why?
|
Transcription Factor RelA | 1 | 2007 | 49 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2008 | 138 | 0.080 |
Why?
|
Fibroblasts | 3 | 2008 | 729 | 0.080 |
Why?
|
Gene Deletion | 1 | 2008 | 329 | 0.080 |
Why?
|
Hematopoiesis | 1 | 2008 | 163 | 0.080 |
Why?
|
Oncogenes | 1 | 2007 | 88 | 0.070 |
Why?
|
Mice, Transgenic | 2 | 2006 | 1540 | 0.070 |
Why?
|
DNA Adducts | 2 | 2009 | 21 | 0.070 |
Why?
|
Nitrosourea Compounds | 2 | 2002 | 9 | 0.070 |
Why?
|
Regression Analysis | 1 | 2008 | 596 | 0.070 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2008 | 173 | 0.070 |
Why?
|
Binding Sites | 2 | 2003 | 1098 | 0.070 |
Why?
|
Disease Models, Animal | 2 | 2013 | 2232 | 0.070 |
Why?
|
Administration, Oral | 2 | 2000 | 684 | 0.070 |
Why?
|
United States | 3 | 2017 | 6665 | 0.070 |
Why?
|
Oxidation-Reduction | 2 | 1998 | 373 | 0.070 |
Why?
|
Nitrosamines | 2 | 1988 | 8 | 0.070 |
Why?
|
Leukocytes, Mononuclear | 2 | 1998 | 196 | 0.070 |
Why?
|
Alkylation | 5 | 2004 | 31 | 0.070 |
Why?
|
Thymidine | 1 | 1985 | 59 | 0.070 |
Why?
|
Activin Receptors, Type I | 1 | 2005 | 12 | 0.070 |
Why?
|
Substrate Specificity | 6 | 1995 | 347 | 0.070 |
Why?
|
Protein Phosphatase 1 | 1 | 2005 | 34 | 0.070 |
Why?
|
Physicians | 1 | 2013 | 673 | 0.070 |
Why?
|
Base Pair Mismatch | 1 | 2005 | 27 | 0.070 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2005 | 40 | 0.070 |
Why?
|
Nerve Tissue Proteins | 1 | 2008 | 503 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2003 | 384 | 0.070 |
Why?
|
Bacterial Proteins | 1 | 1991 | 864 | 0.070 |
Why?
|
Neoplasms, Experimental | 1 | 2007 | 269 | 0.070 |
Why?
|
Crosses, Genetic | 1 | 2005 | 171 | 0.070 |
Why?
|
Cell Transformation, Viral | 1 | 2005 | 40 | 0.070 |
Why?
|
Mice, Mutant Strains | 1 | 2005 | 229 | 0.070 |
Why?
|
Random Allocation | 1 | 2005 | 332 | 0.060 |
Why?
|
Glutathione Peroxidase | 1 | 2004 | 24 | 0.060 |
Why?
|
Dimethylnitrosamine | 1 | 1984 | 4 | 0.060 |
Why?
|
Diethylnitrosamine | 1 | 1984 | 7 | 0.060 |
Why?
|
Polydeoxyribonucleotides | 1 | 1984 | 5 | 0.060 |
Why?
|
Aziridines | 1 | 2004 | 9 | 0.060 |
Why?
|
Poly T | 1 | 1984 | 2 | 0.060 |
Why?
|
Doxorubicin | 2 | 2013 | 295 | 0.060 |
Why?
|
Procaine | 1 | 2004 | 11 | 0.060 |
Why?
|
Clinical Trials as Topic | 4 | 2014 | 1169 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2009 | 589 | 0.060 |
Why?
|
Organ Size | 1 | 2005 | 364 | 0.060 |
Why?
|
Cattle | 3 | 1999 | 376 | 0.060 |
Why?
|
Sequence Homology, Amino Acid | 2 | 2003 | 416 | 0.060 |
Why?
|
Hydroxamic Acids | 1 | 2004 | 49 | 0.060 |
Why?
|
Plasmids | 2 | 2003 | 287 | 0.060 |
Why?
|
Odds Ratio | 2 | 2019 | 678 | 0.060 |
Why?
|
Germ-Line Mutation | 2 | 2020 | 329 | 0.060 |
Why?
|
Computer Simulation | 1 | 2009 | 1078 | 0.060 |
Why?
|
Homozygote | 1 | 2004 | 200 | 0.060 |
Why?
|
Sarcoma | 1 | 2006 | 212 | 0.060 |
Why?
|
Genes, ras | 3 | 2009 | 96 | 0.060 |
Why?
|
Drug Combinations | 1 | 2004 | 224 | 0.060 |
Why?
|
NF-kappa B | 1 | 2007 | 444 | 0.060 |
Why?
|
Gene Expression Regulation, Enzymologic | 2 | 2003 | 214 | 0.060 |
Why?
|
Protein Kinases | 1 | 2005 | 209 | 0.060 |
Why?
|
Annexin A5 | 1 | 2003 | 20 | 0.060 |
Why?
|
Indoles | 1 | 2005 | 318 | 0.060 |
Why?
|
Transcription Initiation Site | 1 | 2003 | 45 | 0.060 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2003 | 79 | 0.060 |
Why?
|
DNA Primers | 3 | 2005 | 543 | 0.060 |
Why?
|
Microscopy, Fluorescence | 2 | 2007 | 425 | 0.060 |
Why?
|
Lung | 2 | 2005 | 1170 | 0.060 |
Why?
|
Subcellular Fractions | 2 | 2007 | 93 | 0.060 |
Why?
|
Isoelectric Focusing | 1 | 2002 | 39 | 0.060 |
Why?
|
Protein Synthesis Inhibitors | 1 | 2002 | 36 | 0.060 |
Why?
|
Dihydrouracil Dehydrogenase (NADP) | 3 | 1999 | 29 | 0.060 |
Why?
|
DNA Topoisomerases, Type II | 2 | 2009 | 20 | 0.050 |
Why?
|
Gene Library | 1 | 2002 | 130 | 0.050 |
Why?
|
Infant | 4 | 2012 | 3045 | 0.050 |
Why?
|
Chlorambucil | 1 | 2001 | 23 | 0.050 |
Why?
|
ErbB Receptors | 1 | 2005 | 485 | 0.050 |
Why?
|
Thrombopoietin | 1 | 2001 | 12 | 0.050 |
Why?
|
Stem Cell Factor | 1 | 2001 | 19 | 0.050 |
Why?
|
Body Mass Index | 2 | 2014 | 770 | 0.050 |
Why?
|
Prospective Studies | 2 | 2020 | 4212 | 0.050 |
Why?
|
Organ Specificity | 2 | 2001 | 258 | 0.050 |
Why?
|
A549 Cells | 1 | 2021 | 39 | 0.050 |
Why?
|
Cloning, Molecular | 1 | 2002 | 646 | 0.050 |
Why?
|
Colony-Forming Units Assay | 1 | 2001 | 40 | 0.050 |
Why?
|
NAD+ Nucleosidase | 1 | 2001 | 2 | 0.050 |
Why?
|
ADP-ribosyl Cyclase | 1 | 2001 | 6 | 0.050 |
Why?
|
ADP-ribosyl Cyclase 1 | 1 | 2001 | 12 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2017 | 468 | 0.050 |
Why?
|
Salvage Therapy | 1 | 2002 | 233 | 0.050 |
Why?
|
Plasma | 1 | 2001 | 50 | 0.050 |
Why?
|
Nervous System Neoplasms | 1 | 2000 | 11 | 0.050 |
Why?
|
Immunophenotyping | 1 | 2001 | 211 | 0.050 |
Why?
|
Risk | 2 | 2012 | 674 | 0.050 |
Why?
|
Biopsy | 2 | 2003 | 1162 | 0.050 |
Why?
|
Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
|
Genes, Reporter | 1 | 2001 | 268 | 0.050 |
Why?
|
Luminescent Proteins | 1 | 2001 | 144 | 0.050 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 26 | 0.050 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2001 | 165 | 0.050 |
Why?
|
Phenanthridines | 1 | 2000 | 24 | 0.050 |
Why?
|
Genetic Association Studies | 2 | 2013 | 294 | 0.050 |
Why?
|
Green Fluorescent Proteins | 1 | 2001 | 305 | 0.050 |
Why?
|
Molecular Structure | 2 | 1998 | 287 | 0.050 |
Why?
|
Hot Temperature | 1 | 2000 | 206 | 0.050 |
Why?
|
Transferases | 2 | 1997 | 24 | 0.050 |
Why?
|
Immunomagnetic Separation | 1 | 1999 | 8 | 0.040 |
Why?
|
Azoxymethane | 1 | 1999 | 82 | 0.040 |
Why?
|
Cell Nucleus | 2 | 1999 | 579 | 0.040 |
Why?
|
Rectum | 1 | 2000 | 146 | 0.040 |
Why?
|
Electrochemistry | 1 | 1999 | 61 | 0.040 |
Why?
|
Carcinogens | 1 | 1999 | 108 | 0.040 |
Why?
|
Luciferases | 2 | 2011 | 118 | 0.040 |
Why?
|
Sequence Alignment | 1 | 2000 | 351 | 0.040 |
Why?
|
Uracil | 1 | 1999 | 72 | 0.040 |
Why?
|
Models, Statistical | 2 | 2014 | 574 | 0.040 |
Why?
|
Prevalence | 1 | 2023 | 1239 | 0.040 |
Why?
|
Patient Outcome Assessment | 1 | 2019 | 84 | 0.040 |
Why?
|
Drug Resistance, Multiple | 1 | 1998 | 20 | 0.040 |
Why?
|
Peroxidases | 1 | 1998 | 34 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2003 | 1135 | 0.040 |
Why?
|
bcl-X Protein | 1 | 1998 | 52 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2001 | 428 | 0.040 |
Why?
|
Esters | 1 | 1998 | 29 | 0.040 |
Why?
|
Protein Binding | 2 | 2007 | 1456 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2012 | 999 | 0.040 |
Why?
|
Molecular Sequence Annotation | 1 | 2018 | 67 | 0.040 |
Why?
|
Macaca mulatta | 1 | 2000 | 459 | 0.040 |
Why?
|
Patient Reported Outcome Measures | 1 | 2019 | 166 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2002 | 426 | 0.040 |
Why?
|
Datasets as Topic | 1 | 2017 | 71 | 0.040 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 1998 | 141 | 0.040 |
Why?
|
Thymidylate Synthase | 1 | 1997 | 13 | 0.040 |
Why?
|
Tumor Stem Cell Assay | 3 | 2009 | 35 | 0.040 |
Why?
|
Injections, Intraperitoneal | 2 | 1994 | 102 | 0.040 |
Why?
|
Leukemia P388 | 2 | 1989 | 3 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 1998 | 189 | 0.040 |
Why?
|
Swine | 1 | 1998 | 555 | 0.040 |
Why?
|
Speech Reception Threshold Test | 1 | 2016 | 4 | 0.040 |
Why?
|
Hearing Loss, Noise-Induced | 1 | 2016 | 4 | 0.040 |
Why?
|
Auditory Threshold | 1 | 2016 | 17 | 0.040 |
Why?
|
Kidney Neoplasms | 1 | 2002 | 621 | 0.040 |
Why?
|
Audiometry, Pure-Tone | 1 | 2016 | 25 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 1999 | 425 | 0.040 |
Why?
|
Neoplasms, Squamous Cell | 1 | 1996 | 19 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 2 | 1989 | 104 | 0.040 |
Why?
|
Rats, Inbred Strains | 2 | 1988 | 312 | 0.040 |
Why?
|
Hearing Loss, Conductive | 1 | 2016 | 17 | 0.040 |
Why?
|
Receptor, ErbB-2 | 1 | 2017 | 223 | 0.030 |
Why?
|
Phenobarbital | 1 | 1995 | 33 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2017 | 384 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2017 | 223 | 0.030 |
Why?
|
Breast | 1 | 2017 | 286 | 0.030 |
Why?
|
Enzyme Induction | 1 | 1995 | 88 | 0.030 |
Why?
|
Azepines | 1 | 2015 | 20 | 0.030 |
Why?
|
RNA, Transfer | 2 | 1988 | 151 | 0.030 |
Why?
|
Lymph Nodes | 1 | 1999 | 530 | 0.030 |
Why?
|
Cytochrome P-450 CYP2B6 | 1 | 2015 | 6 | 0.030 |
Why?
|
Cytochrome P-450 CYP2C19 | 1 | 2015 | 7 | 0.030 |
Why?
|
Prednisone | 1 | 2016 | 258 | 0.030 |
Why?
|
Hydroxylation | 1 | 2015 | 16 | 0.030 |
Why?
|
Cytochrome P-450 CYP2C9 | 1 | 2015 | 21 | 0.030 |
Why?
|
Deuterium | 1 | 2015 | 33 | 0.030 |
Why?
|
Pharmacogenomic Testing | 1 | 2016 | 97 | 0.030 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2015 | 43 | 0.030 |
Why?
|
Isotope Labeling | 1 | 2015 | 51 | 0.030 |
Why?
|
Neural Stem Cells | 1 | 2015 | 58 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 238 | 0.030 |
Why?
|
Bevacizumab | 1 | 2016 | 281 | 0.030 |
Why?
|
Catalysis | 1 | 2015 | 203 | 0.030 |
Why?
|
Triazoles | 1 | 2015 | 96 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2008 | 1673 | 0.030 |
Why?
|
DNA Polymerase II | 1 | 1994 | 7 | 0.030 |
Why?
|
DNA Polymerase I | 1 | 1994 | 9 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 1999 | 1991 | 0.030 |
Why?
|
Metabolic Clearance Rate | 1 | 2014 | 121 | 0.030 |
Why?
|
Protein Array Analysis | 1 | 2014 | 50 | 0.030 |
Why?
|
Cell Growth Processes | 1 | 2014 | 83 | 0.030 |
Why?
|
Body Composition | 1 | 2014 | 68 | 0.030 |
Why?
|
Databases, Factual | 1 | 2017 | 812 | 0.030 |
Why?
|
Genetics, Medical | 1 | 2014 | 52 | 0.030 |
Why?
|
Absorptiometry, Photon | 1 | 2014 | 99 | 0.030 |
Why?
|
Systems Biology | 1 | 2014 | 42 | 0.030 |
Why?
|
Registries | 1 | 2017 | 702 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2016 | 379 | 0.030 |
Why?
|
Idoxuridine | 1 | 1993 | 16 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 2019 | 1937 | 0.030 |
Why?
|
Species Specificity | 2 | 1993 | 678 | 0.030 |
Why?
|
Cladribine | 1 | 2013 | 35 | 0.030 |
Why?
|
Simvastatin | 1 | 2014 | 106 | 0.030 |
Why?
|
Dimethylhydrazines | 1 | 1993 | 2 | 0.030 |
Why?
|
Galectin 3 | 1 | 2013 | 17 | 0.030 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2013 | 66 | 0.030 |
Why?
|
In Situ Nick-End Labeling | 1 | 2013 | 121 | 0.030 |
Why?
|
Solubility | 1 | 1994 | 177 | 0.030 |
Why?
|
Azacitidine | 1 | 2014 | 137 | 0.030 |
Why?
|
Suppression, Genetic | 1 | 2013 | 30 | 0.030 |
Why?
|
RNA Isoforms | 1 | 2012 | 5 | 0.030 |
Why?
|
Necrosis | 1 | 2013 | 204 | 0.030 |
Why?
|
Interferon-alpha | 3 | 2000 | 233 | 0.030 |
Why?
|
Cysteine | 1 | 1993 | 135 | 0.030 |
Why?
|
GATA3 Transcription Factor | 1 | 2013 | 48 | 0.030 |
Why?
|
Cholesterol, LDL | 1 | 2014 | 222 | 0.030 |
Why?
|
Kidney Tubules | 1 | 2013 | 94 | 0.030 |
Why?
|
Pilot Projects | 1 | 1995 | 839 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2012 | 43 | 0.030 |
Why?
|
Thionucleosides | 1 | 2012 | 8 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2000 | 1075 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2013 | 70 | 0.030 |
Why?
|
Caspase 9 | 1 | 2012 | 48 | 0.030 |
Why?
|
Deoxyadenosines | 1 | 2012 | 23 | 0.030 |
Why?
|
Chromatin | 1 | 2015 | 380 | 0.030 |
Why?
|
Purines | 1 | 1992 | 91 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2014 | 361 | 0.030 |
Why?
|
Models, Neurological | 1 | 2015 | 405 | 0.030 |
Why?
|
Gene-Environment Interaction | 1 | 2013 | 103 | 0.030 |
Why?
|
Histones | 1 | 2014 | 311 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 1993 | 164 | 0.030 |
Why?
|
Cell-Free System | 1 | 1991 | 51 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2016 | 1823 | 0.030 |
Why?
|
DNA, Single-Stranded | 1 | 1992 | 92 | 0.030 |
Why?
|
MutL Protein Homolog 1 | 1 | 2011 | 33 | 0.030 |
Why?
|
Melanoma | 1 | 1996 | 454 | 0.030 |
Why?
|
MutS Homolog 2 Protein | 1 | 2011 | 30 | 0.030 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2011 | 72 | 0.030 |
Why?
|
Cytoskeleton | 1 | 2013 | 193 | 0.030 |
Why?
|
Cardiovascular Diseases | 2 | 2010 | 827 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2012 | 253 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 1995 | 894 | 0.020 |
Why?
|
Immunohistochemistry | 3 | 2006 | 1753 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 853 | 0.020 |
Why?
|
Genes, X-Linked | 1 | 2011 | 37 | 0.020 |
Why?
|
Paresthesia | 1 | 2010 | 16 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2016 | 1801 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1991 | 376 | 0.020 |
Why?
|
Infertility, Male | 1 | 2010 | 24 | 0.020 |
Why?
|
Employment | 1 | 2010 | 52 | 0.020 |
Why?
|
Enzyme Activation | 1 | 1991 | 692 | 0.020 |
Why?
|
Tissue Extracts | 1 | 1990 | 24 | 0.020 |
Why?
|
Thrombocytopenia | 2 | 2006 | 183 | 0.020 |
Why?
|
Mitoguazone | 1 | 1989 | 2 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 864 | 0.020 |
Why?
|
Protein Conformation | 1 | 2012 | 881 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 1990 | 188 | 0.020 |
Why?
|
Neoplasm Metastasis | 2 | 2005 | 1056 | 0.020 |
Why?
|
Thermodynamics | 1 | 2010 | 309 | 0.020 |
Why?
|
Combined Modality Therapy | 3 | 2000 | 1685 | 0.020 |
Why?
|
Renal Insufficiency | 1 | 2010 | 114 | 0.020 |
Why?
|
RUNX1 Translocation Partner 1 Protein | 1 | 2009 | 8 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 1990 | 307 | 0.020 |
Why?
|
Glucuronides | 1 | 2009 | 34 | 0.020 |
Why?
|
Fatigue | 1 | 2010 | 174 | 0.020 |
Why?
|
Organic Anion Transporters | 1 | 2009 | 27 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 1995 | 736 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1990 | 318 | 0.020 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2009 | 52 | 0.020 |
Why?
|
Research Design | 1 | 2012 | 594 | 0.020 |
Why?
|
Bilirubin | 1 | 2009 | 125 | 0.020 |
Why?
|
Hepatocyte Nuclear Factor 1-alpha | 1 | 2009 | 80 | 0.020 |
Why?
|
Pulmonary Fibrosis | 1 | 2010 | 123 | 0.020 |
Why?
|
Disease Progression | 2 | 2005 | 1531 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2009 | 128 | 0.020 |
Why?
|
Calcium | 1 | 1993 | 1156 | 0.020 |
Why?
|
Thiosemicarbazones | 1 | 2008 | 6 | 0.020 |
Why?
|
Methemoglobinemia | 1 | 2008 | 10 | 0.020 |
Why?
|
Drug Hypersensitivity | 1 | 2008 | 37 | 0.020 |
Why?
|
DNA Glycosylases | 1 | 1988 | 24 | 0.020 |
Why?
|
Ovary | 1 | 1989 | 257 | 0.020 |
Why?
|
Models, Molecular | 1 | 2012 | 1286 | 0.020 |
Why?
|
Glucuronosyltransferase | 1 | 2009 | 184 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 2010 | 252 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2010 | 429 | 0.020 |
Why?
|
Microsatellite Instability | 1 | 2007 | 43 | 0.020 |
Why?
|
Informatics | 1 | 2007 | 5 | 0.020 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2007 | 137 | 0.020 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2007 | 75 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2009 | 325 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2008 | 118 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2017 | 8477 | 0.020 |
Why?
|
Forecasting | 1 | 2008 | 304 | 0.020 |
Why?
|
RNA, Ribosomal | 1 | 1987 | 60 | 0.020 |
Why?
|
Reference Values | 1 | 2008 | 674 | 0.020 |
Why?
|
Hydroxyurea | 2 | 2000 | 239 | 0.020 |
Why?
|
Cardiovascular Agents | 1 | 2007 | 56 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2009 | 381 | 0.020 |
Why?
|
Translocation, Genetic | 1 | 2007 | 265 | 0.020 |
Why?
|
Leucovorin | 2 | 1997 | 218 | 0.020 |
Why?
|
Tachycardia, Supraventricular | 1 | 2006 | 16 | 0.020 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2006 | 23 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2007 | 420 | 0.020 |
Why?
|
Poly (ADP-Ribose) Polymerase-1 | 1 | 2005 | 21 | 0.020 |
Why?
|
Pyridines | 1 | 2008 | 310 | 0.020 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2007 | 134 | 0.020 |
Why?
|
Leiomyosarcoma | 1 | 2006 | 40 | 0.020 |
Why?
|
Genetics, Population | 1 | 2008 | 394 | 0.020 |
Why?
|
Cognition | 1 | 2010 | 570 | 0.020 |
Why?
|
Consensus Sequence | 1 | 2005 | 64 | 0.020 |
Why?
|
Patient Selection | 1 | 2009 | 685 | 0.020 |
Why?
|
Anemia | 1 | 2006 | 128 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2005 | 205 | 0.020 |
Why?
|
Toxicity Tests | 1 | 2004 | 13 | 0.020 |
Why?
|
Recurrence | 1 | 2008 | 1139 | 0.020 |
Why?
|
Lung Diseases | 1 | 2007 | 263 | 0.020 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 2003 | 4 | 0.020 |
Why?
|
Leukemia L1210 | 1 | 1983 | 12 | 0.020 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2003 | 6 | 0.020 |
Why?
|
RNA | 1 | 1988 | 560 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2005 | 301 | 0.010 |
Why?
|
Remission Induction | 2 | 1997 | 722 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2007 | 394 | 0.010 |
Why?
|
Life Tables | 1 | 2002 | 48 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 1830 | 0.010 |
Why?
|
Selenoproteins | 1 | 2001 | 19 | 0.010 |
Why?
|
Gliosarcoma | 1 | 2000 | 7 | 0.010 |
Why?
|
Drug Implants | 1 | 2000 | 34 | 0.010 |
Why?
|
Rats, Inbred F344 | 1 | 2000 | 156 | 0.010 |
Why?
|
Stereotaxic Techniques | 1 | 2000 | 69 | 0.010 |
Why?
|
Benzophenanthridines | 1 | 2000 | 23 | 0.010 |
Why?
|
Alkaloids | 1 | 2000 | 45 | 0.010 |
Why?
|
Tretinoin | 1 | 2000 | 126 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2000 | 468 | 0.010 |
Why?
|
Protein Kinase C | 1 | 2000 | 270 | 0.010 |
Why?
|
Cerebellar Neoplasms | 1 | 1999 | 36 | 0.010 |
Why?
|
Rats, Nude | 1 | 1997 | 22 | 0.010 |
Why?
|
Injections, Intra-Arterial | 1 | 1997 | 33 | 0.010 |
Why?
|
Feasibility Studies | 1 | 1999 | 751 | 0.010 |
Why?
|
Radiography | 1 | 1999 | 813 | 0.010 |
Why?
|
Tetrahydrofolates | 1 | 1996 | 13 | 0.010 |
Why?
|
Stereoisomerism | 1 | 1996 | 102 | 0.010 |
Why?
|
Preoperative Care | 1 | 1998 | 394 | 0.010 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 1996 | 68 | 0.010 |
Why?
|
Cell Compartmentation | 1 | 1996 | 69 | 0.010 |
Why?
|
Procarbazine | 1 | 1995 | 40 | 0.010 |
Why?
|
Cytoplasm | 1 | 1996 | 281 | 0.010 |
Why?
|
Bile | 1 | 1994 | 57 | 0.010 |
Why?
|
Topotecan | 1 | 1994 | 45 | 0.010 |
Why?
|
Protein Structure, Secondary | 1 | 1995 | 330 | 0.010 |
Why?
|
Antimutagenic Agents | 1 | 1993 | 6 | 0.010 |
Why?
|
Biogenic Polyamines | 1 | 1993 | 1 | 0.010 |
Why?
|
Ornithine Decarboxylase | 1 | 1993 | 8 | 0.010 |
Why?
|
Infant, Newborn | 2 | 1991 | 2378 | 0.010 |
Why?
|
Monocytes | 1 | 1994 | 214 | 0.010 |
Why?
|
Diploidy | 1 | 1991 | 30 | 0.010 |
Why?
|
Saccharomyces cerevisiae | 1 | 1995 | 434 | 0.010 |
Why?
|
Diet | 1 | 1993 | 443 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 1991 | 526 | 0.010 |
Why?
|
Colon | 1 | 1993 | 496 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 1996 | 1204 | 0.010 |
Why?
|
N-Glycosyl Hydrolases | 1 | 1988 | 7 | 0.010 |
Why?
|
Mammals | 1 | 1988 | 227 | 0.000 |
Why?
|
Thymus Gland | 1 | 1985 | 195 | 0.000 |
Why?
|
Skin | 1 | 1985 | 554 | 0.000 |
Why?
|